Nanomedicine Journal

Nanomedicine Journal

Iopamidol-loaded dendrimers for enhanced computed tomography imaging: synthesis, characterization, and in vivo evaluation

Document Type : Research Paper

Authors
1 Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2 Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran
3 Research Center for Nuclear Medicine, Shariati Hospital, Tehran, Iran
4 Iran Ministry of Health and Medical Education, Deputy Ministry for Education, Tehran, Iran
5 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
6 Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Objective(s): This study evaluated second-generation anionic linear globular dendrimers (G2-ALGD) as a nanocarrier platform to improve the physicochemical properties, imaging performance, and safety profile of iopamidol.
Materials and Methods: G2-ALGDs were synthesized via polyethylene glycol (PEG)-citric acid coupling and passively loaded with iopamidol (D-IPM). The formulation was characterized by Dynamic Light Scattering (DLS), Fourier transform infrared spectroscopy (FT-IR), and Transmission electron microscopy (TEM). In vitro drug release was assessed at pH 5.8 and 7.4. Long-term stability was evaluated over 90 days under different storage conditions. Cytocompatibility was assessed using an MTT assay in HEK-293 cells, and imaging performance was evaluated by micro-computed tomography (micro-CT) in Balb/c mice.
Results: Iopamidol loading increased particle size from 102.9 ± 8.7 to 129.8 ± 10.4 nm and shifted the zeta potential from −27.33 ± 1.75 to −0.07 ± 1.28 mV. FT-IR confirmed successful loading, while TEM revealed enhanced crystallinity. Drug encapsulation efficiency reached 43%. Drug release was pH-dependent, with significantly greater release at pH 5.8 (p < 0.0001). The formulation remained stable under refrigerated and lyophilized conditions but degraded at room temperature after 30 days. D-IPM was non-cytotoxic at concentrations ≤125 μg/mL. D-IPM also produced greater CT contrast (3985.06 ± 312.9 vs. 2483.61 ± 215.4 HU) and prolonged in vivo retention, evidenced by reduced bladder accumulation.
Conclusions: Dendrimer-loaded iopamidol demonstrated improved biocompatibility, stability, and CT imaging performance, highlighting its potential as a next-generation CT contrast agent.

Graphical Abstract

Iopamidol-loaded dendrimers for enhanced computed tomography imaging: synthesis, characterization, and in vivo evaluation
Keywords
Subjects

1.    Sun Z, Silberstein J, Vaccarezza M. Cardiovascular computed tomography in the diagnosis of cardiovascular disease: beyond lumen assessment. J Cardiovasc Dev Dis. 2024;11(1):22.
2.    So A, Nicolaou S. Spectral computed tomography: fundamental principles and recent developments. Korean J Radiol. 2021;22(1):86-96.
3.    Parillo M, van der Molen AJ, Asbach P, Elsholtz FHJ, Laghi A, Ronot M, et al. The role of iodinated contrast media in computed tomography structured reporting and data systems (RADS): a narrative review. Quant Imaging Med Surg. 2023;13(11):7621-7631.
4.    Spampinato MV, Abid A, Matheus MG. Current radiographic iodinated contrast agents. Magn Reson Imaging Clin N Am. 2017;25(4):697-704.
5.    Joshi MP, Chaudhari A, Kharkar PS, Joshi SV. Chemistry of iodinated contrast media (ICM): A mini review. Mini Rev Org Chem. 2021;18(7):885-901.
6.    Joaquim JJ, Matos C, Mateos-Campos R. Safety asssessment of iopromide contrast media: a narrative review focusing on adverse events. Curr Issues Pharm Med Sci. 2023;36(3):163-7.
7.    England A, Rawashdeh M, Moore N, Young R, Curran G, McEntee MF. More sustainable use of iodinated contrast media - Why? Radiography (Lond). 2024;30 Suppl 1:74-80.
8.    Lee T, Kim WK, Kim AJ, Ro H, Chang JH, Lee HH, et al. Low-osmolar vs. iso-osmolar contrast media on the risk of contrast-induced acute kidney injury: a propensity score matched study. Front Med (Lausanne). 2022;9:862023.
9.    Andreucci M, Faga T, Pisani A, Sabbatini M, Russo D, Michael A. The choice of the iodinated radiographic contrast media to prevent contrast‐induced nephropathy. Adv Nephrol. 2014;2014(1):691623.
10.  Barrett BJ, Parfrey PS, Vavasour HM, O'Dea F, Kent G, Stone E. A comparison of nonionic, low-osmolality radiocontrast agents with ionic, high-osmolality agents during cardiac catheterization. N Engl J Med. 1992;326(7):431-436.
11.  Mruk B. Renal safety of iodinated contrast media depending on their osmolarity–current outlooks. Pol J Radiol. 2016;81:157.
12.  Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int. 2005;68(5):2256-2263.
13.  Katholi RE. Contrast-induced nephropathy-choice of contrast agents to reduce renal risk. Am Heart Hosp J. 2009;7(1):45-49.
14.  Manual ACR. On contrast media. Virginia (VA), USA: American College of Radiology. 2020.
15.  Bolten JS, Mancuso RV, Roos NJ, Mayr A, Puligilla RD, Kraus L, et al. Nephrotoxicity of iopamidol is associated with mitochondrial impairment in human cell and teleost models. Toxicol Appl Pharmacol. 2023;466:116493.
16.  Asy’ari AH, Rahaju AS, Mustika A. Histopathology and renal function in wistar rats after intravascular injection of iodinated contrast media iohexol and iopamidol. Syntax Lit J Ilm Indones. 2022;7(1):361.
17.  Shilo M, Reuveni T, Motiei M, Popovtzer R. Nanoparticles as computed tomography contrast agents: current status and future perspectives. Nanomedicine (Lond). 2012;7(2):257-269.
18.  Cormode DP, Naha PC, Fayad ZA. Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol Imaging. 2014;9(1):37-52.
19.  De La Vega JC, Hafeli UO. Utilization of nanoparticles as X-ray contrast agents for diagnostic imaging applications. Contrast Media Mol Imaging. 2015;10(2):81-95.
20.  Alamos-Musre S, Beltran-Chacana D, Moyano J, Marquez-Miranda V, Duarte Y, Miranda-Rojas S, et al. From structure to function: the promise of pamam dendrimers in biomedical applications. Pharmaceutics. 2025;17(7).
21.  Fadaei MR, Fadaei MS, Kheirieh AE, Hatami H, Rahmanian-Devin P, Tayebi-Khorrami V, et al. Overview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications. Int J Pharm X. 2025;10:100390.
22.  Kanani-Jazi MH, Akbari S. Host–guest chemistry and functional versatility of dendritic nanomaterials in advanced applications. Nanoscale Adv Mater. 2025;2(2):111-120.
23.  Derakhshan S, Shafiee Ardestani M, Zadeh Mehrizi T, Bitarafan-Rajabi A, Jokar S, Pirali Hamedani M, et al. (99m)Tc-SNW-1 nanoparticle labeling and its biodistribution/pathological evaluations. J Labelled Comp Radiopharm. 2025;68(9-10):e4160.
24.  Rasoulianshiadehi M, Zadeh Mehrizi T, Eshrati B, Shafiee Ardestani M. Advances in targeted cancer imaging using galactose-modified polymeric nanoparticles: A systematic review. Iran J Nucl Med. 2026;34(1):32-47.
25.  Ajdary N, Davoudi M, Zadeh Mehrizi T, Shafiee Ardestani M, Nequi Marnani H, Ebrahimi Shahmabadi H, et al. Development and characterization of colloidally stable dendrimer–botox conjugates for targeted muscle delivery and radiolabeled imaging. Pharm Sci. 2026;32(2):201-218.
26.  Mohammadzadeh P, Cohan RA, Ghoreishi SM, Bitarafan-Rajabi A, Ardestani MS. AS1411 aptamer-anionic linear globular dendrimer g2-iohexol selective nano-theranostics. Sci Rep. 2017;7(1):11832.
27.  Assadi A, Najafabadi VS, Shandiz SA, Boroujeni AS, Ashrafi S, Vaziri AZ, et al. Novel chlorambucil-conjugated anionic linear-globular PEG-based second-generation dendrimer: in vitro/in vivo improved anticancer activity. Onco Targets Ther. 2016;9:5531-5543.
28.  Bober Z, Bartusik-Aebisher D, Aebisher D. Application of dendrimers in anticancer diagnostics and therapy. Molecules. 2022;27(10):3237.
29.  Mirzaei M, Mehravi B, Ardestani MS, Ziaee SAM, Pourghasem P. In vitro evaluation of Gd 3+-anionic linear globular dendrimer-monoclonal antibody: potential magnetic resonance imaging contrast agents for prostate cancer cell imaging. Mol Imaging Biol. 2015;17:770-776.
30.  Hashempour Alamdari N, Alaei-Beirami M, Sadat Shandiz SA, Hejazinia H, Rasouli R, Saffari M, et al. Gd3+‐asparagine‐anionic linear globular dendrimer second‐generation G2 complexes: novel nanobiohybrid theranostics. Contrast Media Mol Imaging. 2017;2017(1):3625729.
31.  Ajdary N, Shafiee Ardestani M, Nequi Marnani H, Eshrati B, Zadeh Mehrizi T. Current strategies in the development of nanoformulations to enhance the stability of botox: a systematic review. AAPS PharmSciTech. 2025;27(1):38.
32.  Namazi H, Adeli M. Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agents. Biomaterials. 2005;26(10):1175-1183.
33.  Ebrahimi S, Sadeghizadeh M, Aghasadeghi M, Shafiee Ardestani M, Behmanesh M. One-step synthesis of anionic peg-citrate G2 dendrimer and evaluation of its cytotoxicity in two cell lines. Pathobiol Res. 2015;17(4):13-24.
34.  Haririan I, Alavidjeh MS, Khorramizadeh MR, Ardestani MS, Ghane ZZ, Namazi H. Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines. Int J Nanomedicine. 2010;5:63-75.
35.  Khosravy MS, Shafiee Ardestani M, Ahangari Cohan R, Doroud D, Amini S, Momen SB, et al. Design, synthesis, physicochemical and immunological characterization of dendrimer-HBsAg conjugate. Vaccine Res. 2014;1(2):24-28.
36.  Pargoo EM, Aghasadeghi MR, Parivar K, Nikbin M, Rahimi P, Ardestani MS. Lamivudine-conjugated and efavirenz-loaded G2 dendrimers: Novel anti-retroviral nano drug delivery systems. IET Nanobiotechnol. 2021;15(7):627-637.
37.  Gao C, Zhang Y, Zhang Y, Li S, Yang X, Chen Y, et al. cRGD-modified and disulfide bond-crosslinked polymer nanoparticles based on iopamidol as a tumor-targeted CT contrast agent. Polym Chem. 2020;11(4):889-899.
38.  Shah S, Rangaraj N, Singh SB, Srivastava S. Exploring the unexplored avenues of surface charge in nano-medicine. Colloid Interface Sci Commun. 2021;42:100406.
39.  Fu Y, Nitecki DE, Maltby D, Simon GH, Berejnoi K, Raatschen HJ, et al. Dendritic iodinated contrast agents with PEG-cores for CT imaging: synthesis and preliminary characterization. Bioconjug Chem. 2006;17(4):1043-1056.
40.  Yin Q, Yap FY, Yin L, Ma L, Zhou Q, Dobrucki LW, et al. Poly(iohexol) nanoparticles as contrast agents for in vivo X-ray computed tomography imaging. J Am Chem Soc. 2013;135(37):13620-13623.
41.  Kale T, Bendale K, Singh KK, Chaudhari P. Albumin based iohexol nanoparticles for computed tomography: an in vivo study. J Biomed Nanotechnol. 2019;15(2):236-247.
42.  Balegamire J, Vandamme M, Chereul E, Si-Mohamed S, Azzouz Maache S, Almouazen E, et al. Iodinated polymer nanoparticles as contrast agent for spectral photon counting computed tomography. Biomater Sci. 2020;8(20):5715-5728.
43.  Jeong Y, Jin M, Kim KS, Na K. Biocompatible carbonized iodine-doped dots for contrast-enhanced CT imaging. Biomater Res. 2022;26(1):27.
44.  Alhasan A, Tajuddin HA, Sani SFA, Ali TH, Hisham S, Mokti MH, et al. Iohexol functionalized Si-Ag: Mn3O4 hybrid nanoparticles based contrast agent for computed tomography imaging. Mater Today Commun. 2022;33:104377.
45.  Kojima C, Umeda Y, Ogawa M, Harada A, Magata Y, Kono K. X-ray computed tomography contrast agents prepared by seeded growth of goldnanoparticles in pegylated dendrimer. Nanotechnol. 2010;21(24):245104.
46.  Feng SJ, Liu CH, Xia XM, Yu BY, Chu GW, Li H, et al. Unraveling the role of pegylation in the anti-aggregation stability of lipid nanoparticles. Nanoscale. 2025;17(47):27530-27537.
47.  Bharadwaj P, Roullin VG, Chain JL. Crossing the blood-brain barrier: advances in dendrimer-based nanocarriers for central nervous system delivery. Nanoscale. 2025;17(40):23202-23227.
48.  Chen Y, Su Y-C, Roffler SR. Polyethylene glycol immunogenicity in nanomedicine. Nat Rev Bioeng. 2025;3(9):742-760.
49.  Devkota L, Bhavane R, Badea CT, Tanifum EA, Annapragada AV, Ghaghada KB. Nanoparticle contrast agents for photon-counting computed tomography: recent developments and future opportunities. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025;17(1):e70004.
50.  Zhang P, Ma X, Guo R, Ye Z, Fu H, Fu N, et al. Organic nanoplatforms for iodinated contrast media in ct imaging. Molecules. 2021;26(23):7063.
51.  Mahdavimehr M, Rahdari T, Nikfarjam N, Ehtesham S, Shafiee Ardestani M, Asghari SM. Development and application of dual-modality tumor-targeting SPIONs for precision breast cancer imaging. Biomater Adv. 2025;172:214236.
52.  Mohammadi E, Amanlou M, Sadat Ebrahimi SE, Hamedani MP, Mahrooz A, Mehravi B, et al. Cellular uptake, imaging and pathotoxicological studies of a novel Gd[iii]–DO3A-butrol nano-formulation. RSC Adv. 2014;4(86):45984-45994. 

Articles in Press, Accepted Manuscript
Available Online from 21 November 2026